It has been found that maintaining adequate doses of chemotherapy is important for the survival of patients with adenocarcinoma

Recently, a study published in the National Journal of comprehensive cancer network found that maintaining adequate doses of chemotherapy, especially in the early stage of the treatment process, is crucial for the survival of patients with medium and high-risk breast cancer Zachary Veitch, M.D., and colleagues evaluated total cumulative dose (TCD), early (5-fluorouracil / epirubicin / cyclophosphamide), and late (docetaxel only) dose reductions for phase I to phase III, hormone receptor positive / negative, and chemotherapy with 5-fluorouracil / epirubicin / cyclophosphamide in combination with docetaxel (2007)- 2014) therapeutic effect on human epidermal growth factor receptor 2 negative breast cancer The researchers noted that of the 1302 patients assessed for dose reduction, 16% were reduced to 85% (202 patients), while the remaining patients were reduced to ≥ 85% (1100 patients; 84%) Patients with TCD ≥ 85% had higher 5-year disease-free survival (DFS) and overall survival (OS) than patients with a dose reduction of < 85% DFS and OS of patients with early dose reduction were significantly lower than those with late dose reduction Multivariate analysis (http://www.chemdrug.com/sell/76/) showed similar results (hazard ratio 1.46 and 1.77, respectively) The dose delay of < 14 days or ≥ 14 days and granulocyte colony stimulating factor had no effect on the results